Abstract | Objectives: The aim of the present study was to investigate a potential relationship between metabolic parameters and steady-state plasma concentrations of olanzapine (OLA) and its metabolite, 4-N'-desmethyl-olanzapine (DMO) in patients with schizophrenia taking therapeutic doses. Methods: Results: Lower plasma DMO concentrations were associated with higher glucose and TG levels and homeostasis model assessment of insulin resistance (HOMA-IR), while higher plasma OLA concentrations were associated with higher CRP and homocysteine levels in the OLA-treated patients with schizophrenia. Conclusion: These results demonstrate that OLA and its metabolite DMO may have different effects on OLA-induced metabolic abnormalities. DMO might have a counteracting effects on glucose- insulin homeostasis and lipid metabolic abnormalities, which suggests that regular measure of various metabolic parameters and drug monitoring on both OLA and DMO are recommended in OLA-treated patients with schizophrenia.
|
Authors | Huimei An, Hongzhen Fan, Yajun Yun, Song Chen, Siyuan Qi, Botao Ma, Jing Shi, Zhiren Wang, Fude Yang |
Journal | Frontiers in psychiatry
(Front Psychiatry)
Vol. 13
Pg. 930457
( 2022)
ISSN: 1664-0640 [Print] Switzerland |
PMID | 35800023
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 An, Fan, Yun, Chen, Qi, Ma, Shi, Wang and Yang. |